Petros pharmaceuticals' proprietary technology demonstrates positive data in pivotal study

Proprietary technology utilizing ai and big data integrations to enable rx to otc switch candidates across multiple indications new york, ny / access newswire / february 25, 2025 / petros pharmaceuticals, inc. (nasdaq:ptpi) ("petros" or the "company"), a company focused on expanding consumer access to medication through over-the-counter ("otc") drug development programs, announces top-line results of its expanded application comprehension ("app comp") study, which determines consumer comprehension of its unique messaging within its proprietary technology. in the study, the company's technology facilitated consumer's understanding of designated critical objectives (with a success threshold of 90% or 85% based on clinical significance of the objective).
PTPI Ratings Summary
PTPI Quant Ranking